We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Gonadorelin (synthetic GnRH)
A synthetic copy of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pituitary to release LH and FSH. Honest appraisal: it has genuine, trial-backed roles as a diagnostic agent (the GnRH/gonadorelin stimulation test) and — delivered in pulses by an infusion pump — for inducing ovulation in hypothalamic amenorrhea and spermatogenesis in men with congenital hypogonadotropic hypogonadism. Its now-trendy use in men's TRT clinics (compounded, to 'maintain testosterone/fertility' alongside testosterone, often replacing hCG) is largely off-label and has NOT been validated in controlled trials for that purpose.
Prescription medication — not a dietary supplement
Gonadorelin is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Gonadorelin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1976–2026 with a typical study size of 92 participants.
Based on 48 studies · 6 meta-analyses · 26 RCTs · 5,747 total participants
Confidence
High confidenceBy outcome
Pulsatile pump-delivered GnRH has solid observational evidence for ovulation induction and spermatogenesis plus a validated diagnostic test, but there are no RCTs or meta-analyses, and the trendy intermittent-injection TRT-clinic use is unvalidated.
38 rigorous studies
30 randomized trials · 7 meta-analyses · 1 systematic reviews
Our evidence rating for Gonadorelin is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
248 trials ongoing or recruiting · 564 completed on ClinicalTrials.gov
216 of the completed trials have posted results
Registered trials show research momentum for Gonadorelin, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), the decapeptide normally released in pulses by the hypothalamus to stimulate the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
It is a prescription drug (historically marketed as Factrel and, for pump use, Lutrelef/Lutrepulse), not a dietary supplement.
Because native GnRH has a very short circulating half-life (minutes), the way it is delivered matters enormously: a single bolus is used diagnostically (the GnRH/gonadorelin stimulation test, where the LH/FSH response distinguishes central precocious puberty, hypogonadotropic hypogonadism, and pubertal staging), whereas treatment of infertility requires pulsatile delivery via a programmable infusion pump that mimics the natural ~90-minute hypothalamic rhythm.
The strongest human evidence is for these two uses.
In women with hypothalamic amenorrhea or congenital GnRH deficiency, pulsatile GnRH reliably induces ovulation and pregnancy, with high cumulative conception rates and — importantly — a lower risk of multiple gestation and ovarian hyperstimulation than exogenous gonadotropins.
In men with idiopathic/congenital hypogonadotropic hypogonadism, pulsatile GnRH induces virilization and spermatogenesis, with outcomes predicted by prior pubertal development, baseline inhibin B, and absence of cryptorchidism.
Crucially, these are the validated indications — and they depend on intact pituitary gonadotropes, pump-delivered pulsatility, and a specific patient population.
The popular men's-TRT-clinic practice of injecting gonadorelin subcutaneously a few times a week (often instead of hCG, to 'keep the testes working' while on exogenous testosterone) is a different proposition: its short half-life makes intermittent subcutaneous bolus dosing pharmacologically very different from pump-delivered pulsatility, and there are essentially no controlled trials demonstrating that this regimen preserves testicular function, intratesticular testosterone, or fertility in men on TRT.
That use is off-label and uncontrolled. So the honest picture is two-tiered: real, evidence-backed diagnostic and pulsatile-fertility uses on one side, and a trendy but largely unvalidated TRT-clinic use on the other.
Gonadorelin is identical to native GnRH; it binds GnRH receptors on anterior-pituitary gonadotrophs, the upstream master switch of the reproductive (hypothalamic-pituitary-gonadal) axis.
Receptor activation triggers secretion of LH and FSH. The response depends on delivery: a single bolus gives an acute diagnostic LH/FSH rise, while sustained pump-delivered pulses (every ~90 min) are needed to drive ongoing gonadal stimulation. Continuous (non-pulsatile) exposure paradoxically desensitizes the pituitary.
Pulsatile LH/FSH stimulates the ovary to grow follicles and ovulate, and the testis to produce testosterone (Leydig cells) and sperm (Sertoli-cell-supported spermatogenesis) — provided the pituitary and gonads are intact.
How Gonadorelin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
This off-label, compounded use is not validated by controlled trials; intermittent sc dosing differs from the pump-delivered pulsatile therapy that the evidence supports. Discuss alternatives (e.g. hCG, sperm banking) with a reproductive endocrinologist.
The gonadorelin/GnRH stimulation test is an established pediatric diagnostic tool, performed under specialist supervision — not a treatment.
Avoid — stimulating the gonadal axis could be harmful; specialist input required.
Fertility use is clinician-supervised and stopped at conception; not for self-administration.
Exogenous androgens suppress the hypothalamic-pituitary axis; the rationale for adding gonadorelin in TRT clinics is to offset this, but whether intermittent sc gonadorelin actually preserves the axis or fertility on TRT is not established by controlled trials.
These drugs occupy or down-regulate the same receptor; co-use is contradictory and would blunt or block the gonadorelin response.
Several drugs alter pituitary gonadotropin responsiveness and can confound the GnRH stimulation test or the therapeutic response.
Tip: Rotate sites; with pump therapy, manage the indwelling catheter site carefully
Tip: Lower than with gonadotropins, but monitor follicles by ultrasound during ovulation induction
Tip: Usually transient
Tip: Sterile technique and site monitoring; subcutaneous route reduces this risk
Gonadorelin has an evidence score of 4/10 — emerging evidence based on 45 indexed studies. A synthetic copy of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pituitary to release LH and FSH. Honest appraisal: it has genuine, trial-backed roles as a diagnostic agent (the GnRH/gonadorelin stimulation test) and — delivered in pulses by an infusion pump — for inducing ovulation in hypothalamic amenorrhea and spermatogenesis in men with congenital hypogonadotropic hypogonadism. Its now-trendy use in men's TRT clinics (compounded, to 'maintain testosterone/fertility' alongside testosterone, often replacing hCG) is largely off-label and has NOT been validated in controlled trials for that purpose. Representative study: PMID 12213860.
The commonly studied dose of Gonadorelin is Prescription-only and delivery-dependent. Diagnostically, a single bolus (e.g. 100 µg) is given. For fertility, pulsatile delivery via an infusion pump is required — historic regimens used ~75 ng/kg/pulse (women, often IV) or 5-25 ng/kg/pulse titrated (men, sc), every ~90 minutes. No validated dietary-supplement dose exists; intermittent subcutaneous bolus dosing as used in some TRT clinics is off-label and not validated.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Gonadorelin — consistent daily use matters more than the time of day. For fertility, dosing is continuous pulsatile delivery by pump (every ~90 min) to mimic the natural hypothalamic rhythm — not a once-daily schedule.
Gonadorelin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are injection-site reaction (pain, redness, swelling), multiple pregnancy / ovarian enlargement (fertility use), headache, flushing, nausea, abdominal discomfort. Use caution if any of these apply to you: Pregnancy (fertility treatment is supervised; not a self-administered agent); Hormone-sensitive tumors / conditions worsened by gonadal stimulation; Use without medical supervision.
HCG (Human Chorionic Gonadotropin)
Mostly mechanism / observationalA placental glycoprotein hormone that acts as a long-acting LH analogue: it binds the LH/CG receptor on testicular Leydig cells (and ovarian theca cells) to drive sex-steroid production. Honest appraisal: it is genuinely well-established for inducing ovulation/the final-maturation 'trigger' in female fertility, for inducing spermatogenesis in men with hypogonadotropic hypogonadism, and for maintaining intratesticular testosterone and sperm production in men on testosterone therapy who want to preserve fertility. Its proven benefits are confined to the gonadal axis — it does not improve systemic longevity or healthspan, and grey-market/compounded sourcing carries real risks.
PT-141
Mostly mechanism / observationalA melanocortin-receptor (MC4R) agonist peptide for low sexual desire. Important honest framing: unlike most 'research peptides', bremelanotide is an FDA-APPROVED prescription drug — Vyleesi, approved 2019 — for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, self-injected subcutaneously on-demand. It has real phase-3 RCTs (the RECONNECT program). The catch: the approved-trial benefit was statistically significant but small (a fraction of a point on desire scales), nausea is very common, and it transiently raises blood pressure. Grey-market 'PT-141' vials sold online are NOT the approved drug and are unregulated.
Sermorelin
Mostly mechanism / observationalAn injectable analogue of growth-hormone-releasing hormone (the first 29 amino acids of GHRH) that stimulates the pituitary to release growth hormone. Honest appraisal: this WAS an FDA-approved prescription drug (Geref) with real human trials — for diagnosing GH deficiency and treating GH-deficient children — but it was discontinued commercially. Its current marketing as a compounded 'anti-aging' peptide is off-label and is NOT what those trials validated.
Argireline
Mostly mechanism / observationalA topical cosmetic peptide — a leave-on skincare ingredient, NOT something you swallow, inject, or take as a supplement, and NOT a drug. Argireline (acetyl hexapeptide-8, also sold as acetyl hexapeptide-3) is a six-amino-acid fragment modelled on the SNAP-25 protein. It is marketed as 'topical Botox' because, in cell systems, it interferes with the SNARE complex that nerve endings use to release neurotransmitter, in theory slightly relaxing the tiny muscle contractions that create expression lines. There ARE real human topical studies — small, short, vehicle-controlled split-face wrinkle trials — and they do show modest reductions in the appearance of fine lines. But the effect sizes are small, several of the trials are industry-linked, and this is a cosmetic effect on wrinkle APPEARANCE, not a health outcome. It is generally well tolerated on skin. This entry exists to describe a cosmetic ingredient honestly, not to recommend an ingestible supplement.
Explore: Best supplements for Women's Health
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 48 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research